A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy
Status:
Recruiting
Trial end date:
2026-02-17
Target enrollment:
Participant gender:
Summary
This trial will seek to extend the preliminary findings of efficacy of MBG453 in combination
with hypomethylating agents (HMA) by evaluating MBG453 in combination with the HMA
azacitidine and the Bcl-2 inhibitor venetoclax. The primary purpose of Part 1 (Safety Run-in)
is to rule out excessive toxicity of MBG453, when administered in combination with
azacitidine and venetoclax. The primary purpose of the combined Part 1 and Part 2 (Safety
run-in and Expansion Part) is to evaluate efficacy of MBG453, when administered in
combination with azacitidine and venetoclax in adult patients with newly diagnosed AML, who
are not suitable for treatment with intensive chemotherapy.